Induction or aggravation of other immune-mediated disorders by disease-modifying therapy in treatment of multiple sclerosis

  • Seyed Mohammad Baghbanian Bualicina Hospital, Mazandaran University of Medical sciences, Sari, Iran
  • Mohammad Ali Sahraian Multiple Sclerosis Research Centre, Sina Hospital, Tehran University of Medical Sciences, Tehran, Iran
Keywords: Interferon-Beta, Glatiramer Acetate, Autoimmune Disease, Multiple Sclerosis

Abstract

Interferon beta (IFN-β) and glatiramer acetate (GA) are the primary therapeutic immunomodulatory agents that interfere with relapsing-remitting multiple sclerosis (RRMS), and the most commonly-used drugs as well. Induction or aggravation of other immune-mediated diseases has been reported following INF-β administration. We have reviewed the reported cases to notify the treating physicians about these rare adverse events. Although co-morbid autoimmune disorders have been reported in patients with MS, the pro-inflammatory role of disease-modifying drugs, especially INF-β, could affect and enhance this co-occurrence. Clinical or laboratory autoimmunity histories suggest the use of GA over INF-β as the treatment of choice.
Published
2018-07-05
How to Cite
1.
Baghbanian SM, Sahraian MA. Induction or aggravation of other immune-mediated disorders by disease-modifying therapy in treatment of multiple sclerosis. IJNL. 17(3).
Section
Review Article(s)